{
  "docId": "019de073-42e0-708e-bbdb-4616fa343de3",
  "docSlug": "252a92bcbab8bda657ee7494bf765251",
  "documentTitle": "BioAtla | Investor Presentation Deck | 37 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 37,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 9,
  "notes": "The slide uses a combination of a comparison table for clinical data and a dot plot for NHP toxicity data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-42e0-708e-bbdb-4616fa343de3/30",
  "deckHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3",
  "deckJsonHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3.json",
  "deckAnchorHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.03,
        "y": 0.215
      },
      "kind": "callout",
      "text": "Research demonstrates challenges and opportunity in combining two Immune Checkpoint Inhibitors. Improves efficacy, but increases adverse events. Greater % of patients discontinue therapy relative to monotherapy.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84737a34-0cdc-47c7-a49c-e52623b52233",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.46,
        "y": 0.54
      },
      "kind": "chart",
      "text": "NHP study GI symptoms dot plot comparing Nivo + Ipi vs Nivo + BA3071",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fe18184-f531-4f46-badf-ca096506d882",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.03,
        "y": 0.56
      },
      "kind": "paragraph",
      "text": "In NHP study, BA3071 achieved similar exposure levels to Ipi analog with significantly less toxicity in combination with nivo.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eecad9f6-1380-457b-9665-7980366d9755",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.11,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*Larkin et al., New Eng. J. Med.,373: 23-34, 2015 **Chang et al., PNAS 118 (9): 1-10, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "deece10e-4655-4cd6-8f8e-fc9da2efadc9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.46,
        "y": 0.24
      },
      "kind": "table",
      "text": "Clinical Endpoint, Nivolumab (PD-1), Nivolumab (PD-1) + Ipilimumab (CTLA4). Progression Free Survival, 6.9 months, 11.5 months. Grade 3 or 4 Adverse Events, 16.3%, 55.0%. Discontinued Treatment, 7.7%, 36.4%.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f47e6bef-9ea3-460b-9472-d0e8dfc0fa7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Best-in-class and potential for disruption of the I/O Market",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "913f2cdc-b898-4338-86db-ea8aa6edd7ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "BA3071 (CAB-CTLA-4)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f3b01f5-cacb-472b-abba-ea7abdb1fcd5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "d9367c26-9de9-4512-9a13-39d3a3e8f556",
      "evidence": "Table comparing clinical endpoints of two drug regimens",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}